


Supplementary Fig. S4 SYRCLE's risk of bias tool for animal studies (6 studies): oncology¹⁻³ and chronic inflammatory disease^{*2-4} studies.



*Da Silva et al² and Ryan et al³ reported nonclinical data supporting both the oncology and chronic inflammatory disease indications.

References

- Hurst S, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and Trastuzumab (Herceptin®). *BioDrugs*. 2014;28(5):451-9.
- da Silva A, et al. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. *Leuk Lymphoma*. 2014;55(7):1609-17.
- Ryan AM, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®). *Toxicol Pathol*. 2014;42(7):1069-81.
- Maity S, et al. A non-innovator version of etanercept for treatment of arthritis. *Biologics*. 2011;39(6):384-95.